Background. Radiation-associated angiosarcoma (RAAS) is a devastating disease occasionally observed in breast cancer patients treated with radiation. Due to its rarity, our knowledge-of disease risk factors, epidemiology, treatment, and outcome-is extremely limited. Therefore, we sought to identify clinicopathologic factors associated with local and distant recurrence and disease-specific survival (DSS). Methods. Radiation-associated angiosarcoma was defined as pathologically confirmed breast or chest wall angiosarcoma arising within a previously irradiated field. A comprehensive search of our institutional tumor registry (1/ 1/93 through 2/28/11) was used to identify patients (n = 95 females). Patient, original tumor, RAAS treatment, and outcome variables were retrospectively retrieved and assembled into a database. Results. The median follow-up for all RAAS patients was 10.3 (range, 2.4-31.8) years. The latency period following radiation exposure ranged from 1.4 to 26 (median, 7) years. One-year and 5-year DSS rates were 93.5 and 62.6 %, respectively. Reduced risk of local recurrence was observed in patients who received chemotherapy (P = 0.0003). In multivariable analysis, size was found to be an independent predictor of adverse outcome (P = 0.015). Conclusions. Our study demonstrates that RAAS exhibits high recurrence rates. It also highlights the need for welldesigned, multicenter, clinical trials to inform the true utility of chemotherapy in this disease.
with an estimated incidence of 0.04-0.15 %. [3] [4] [5] [6] [7] Yap et al. 8 reported a Surveillance, Epidemiology and End Results (SEER) study of breast cancer patient second malignancies (n = 270,000), demonstrating that angiosarcoma is the most prevalent postradiation secondary sarcoma at this site. Given their long latency period (range, 3-20 years), RAAS underreporting is likely and its true incidence therefore is higher. 7, [9] [10] [11] Moreover, as the number of patients treated with adjuvant radiotherapy who become long-term survivors increases, RAAS incidence may likewise increase.
Due to the rarity of RAAS, most reports are anecdotal or small institutional series. Accordingly, we reviewed our experience with breast RAAS, the largest single-institutional series reported to date, seeking to identify clinicopathologic factors prognostic for disease-free, local, and distant recurrence-free survival.
METHODS
With the approval of the Institutional Review Board of The University of Texas MD Anderson Cancer Center (UTMDACC), we identified all patients diagnosed with RAAS of the breast or chest wall from January 1, 1993 to February 28, 2011 who met these criteria: (1) history of radiation to the breast/chest before development of angiosarcoma; (2) angiosarcoma occurrence within radiotherapy fields; and (3) angiosarcoma histologically verified by a UTMDACC pathologist.
The date of RAAS histologic confirmation was defined as the date of diagnosis. For tumor size, the maximum dimension determined by radiologic or pathologic assessment was utilized. A microscopically positive surgical margin was defined as tumor within \1 mm of the inked margin. Patients with more than one lesion were considered to have multifocal disease. Local recurrence was considered as any recurrence at the primary site without metastasis.
Clinicopathologic variables included: (1) patient factors: age at diagnosis (B50 or [50 years); (2) tumor factors, e.g., microscopic margins (negative or positive), grade (low/intermediate, high) and size (B10 or [10 cm); (3) surgical procedure; (4) neoadjuvant/adjuvant treatment. The tumor grade was based on that stated in the pathology report given at the time the slides were reviewed originally. Locally advanced disease was defined as tumor involving the chest wall or axilla, and/or measuring \10 cm in size. Patients with atypical vascular lesions (AVLs) were excluded, given that AVLs and cutaneous angiosarcomas may represent two histologically distinct entities.
Local recurrence-free survival was determined as the time from the initial RAAS treatment to recurrence at any previously irradiated site. Deaths due to disease were treated as a disease-specific survival (DSS) endpoint; other deaths were treated as censored observations. Overall survival (OS) was defined as time from initial RAAS diagnosis until death from any cause. Surviving patients and those lost to follow-up were censored on the date of last follow-up. DSS and OS were calculated by Kaplan and Meier methods. 12 Significance between survival curves was evaluated using log-rank tests and multivariable Cox proportional hazards regression analysis.
13 P \ 0.05 was considered significant.
RESULTS

Breast Cancer History
Ninety-five patients previously treated with breastconserving surgery or mastectomy and radiation therapy (from January 1, 1993 to February 28, 2011) were evaluated at UTMDACC for RAAS of the breast or chest 
Radiation-Associated Angiosarcoma Presentation
All patients [median age, 71 (range, 34-92) years] were free of breast carcinoma at the time of RAAS diagnosis ( Table 2 ). The median latency period was 7 (range, 1.4-26) years. All patients presented with skin changes, including skin nodules (n = 60), rash/erythema (n = 19), macular lesion (n = 7), or ulceration (n = 3). The median time from symptom to diagnosis was 3 (range, 0-11) months. Patients commonly presented with multifocal disease (70 %), with primary lesions located in the breast (62 %) and in the chest wall/axilla/arm (38 %). At presentation, 96 % of patients had localized disease; only 4 % had metastases. Ten patients had clinically apparent lymphedema in the ipsilateral arm.
Treatment Characteristics
All patients presenting with localized RAAS underwent surgical evaluation; 89 patients (94 %) underwent resection. Sixty-two (70 %) underwent surgery elsewhere and 27 (30 %) underwent definitive surgery at UTMDACC. Total mastectomy without axillary node dissection was most commonly performed (55 %), followed by wide local excision for those patients with prior mastectomy (30 %; Table 2 ). Four patients underwent MRM, seven had bilateral mastectomies, and two were treated with forequarter amputation. Reconstructive surgery was performed on 24 patients, including 14 who underwent myocutaneous flaps (i.e., advancement flap, latissimus dorsi, or transverse rectus abdominis myocutaneous flap); ten patients received skin grafts. Two patients with locally advanced disease did not undergo surgical treatment due to disease progression and medical comorbidities. There were no postoperative mortalities.
Forty-nine patients (52 %) received chemotherapy in addition to surgical resection ( Table 2) . Twelve of the patients with localized disease (13 %) received neoadjuvant therapy, all of whom presented with extensive cutaneous 
Pathologic Findings
The diagnosis of RAAS was established histologically in all cases (57 % high grade; 19 % low/intermediate grade; in 24 %, grade was not reported; Table 2 ). All tumors involved skin; no patients had tumors limited to the breast parenchyma. Tumors ranged in size from 0.2 to 24 (median, 5) cm. Eight patients had positive margins (four each R1 or R2 resections). Two of the R1 patients were re-excised with resultant R0 margins, one of whom received subsequent adjuvant therapy. The other two R1 resection patients were treated with adjuvant therapy and close follow-up. Of the four R2 margin patients, one underwent re-excision with subsequent negative margins and three were treated with adjuvant therapy alone, due to unresectability or surgically prohibitive medical comorbidities. For the four patients who underwent MRM, none of the lymph nodes examined were positive for angiosarcoma.
Local and Distant Treatment Failure
After median follow-up of 10.8 (range, 2.4-31.8) years, local recurrence following R0/R1 resection was observed in 48 % of patients (n = 46). Eleven patients developed second local recurrences. Distant metastasis occurred in 26 patients (27 %). Median time to local and distant recurrence was 1.8 (range, 0.1-15.8) years and 3.0 (range, 0.2-15.8) years, respectively. Thirteen patients (14 %) who developed local recurrence had synchronous distant metastasis. The most common site for distant metastasis was the lung (n = 18; 3 patients also had liver metastasis) followed by the liver (n = 5).
Cox regression multivariable analyses were used to identify factors associated with local and distant recurrence-free survival. We observed a local recurrence risk reduction in patients who received chemotherapy and surgical resection [hazard ratio (HR) = 0.35; 95 % confidence interval (CI), 0.15-0.8; P = 0.012]. Age, grade, margin status, and tumor size were not associated with local recurrence-free survival. The limited number of patients precluded any definite conclusion regarding the role of chemotherapy in the prevention of multiple recurrences. High grade was associated with decreased distant recurrence-free survival (HR = 4.23; 95 % CI, 1.39-12.89; P = 0.011). Age, margin status, tumor size, and use of chemotherapy were not associated with distant recurrence-free survival. 
Survival Outcomes
Of the 95 patients, 30 died of disease and 17 patients died of other causes. The 1-, 2-, and 5-year OS was 91, 78, and 54 %, respectively. The 1-, 2-, and 5-year DSS was 94, 84, and 63 %, respectively (Table 3) . Patients who developed metastatic disease or local recurrence had significantly worse DSS than those who did not (P = 0.0002 ; Fig. 1a) ; patients who presented initially with locally advanced disease or metastasis had worse DSS than patients who presented with localized primary tumors (P = 0.01; Fig. 1b (Table 4 ; Kaplan-Meir curves; Fig. 1a, d ). Grade and adjuvant/neoadjuvant treatment were not associated with improved survival. Size was the only independent adverse outcome predictor on multivariable analysis (P = 0.015; Table 4 ).
DISCUSSION
Given the rarity and variability of clinical presentation, RAAS diagnosis often is delayed and management strategies are inconsistent. Some studies have proposed that one of the differences between RAAS of the breast and other radiation-associated sarcomas is the relatively short interval between radiation therapy and the development of the angiosarcoma. 7, [14] [15] [16] [17] [18] The mean time interval between radiation therapy and subsequent sarcoma onset is approximately 10 years. 1, 19, 20 For instance, postradiation bone sarcoma series report a median latency range from 14 to 17 years. 1, 19, 20 We observed eight cases occurring in \4 years after radiation treatment. Although RAAS presents a distinct clinical pattern, the difference between radiation-associated versus sporadic lesions remains unverified. The establishment of genetic differences between sporadic and radiation-associated angiosarcomas will facilitate discrimination between these two entities. Recent data have demonstrated that radiation-induced angiosarcomas are characterized by a consistent amplification of the c-MYC oncogene, which less often is observed in sporadic lesions. 21 Furthermore, a signature of 135 genes has been identified which distinguishes radiation-induced from sporadic sarcomas. 22 In the future, better understanding of these molecular features will assist us in the differentiation of radiation-induced versus sporadic lesions.
Most of our patients (94 %) underwent surgical resection. Only one received palliative radiation; reirradiation is usually contraindicated in RAAS due to the cumulative risk of severe toxicity. However, complete RAAS response rates using radiotherapy with hyperthermia have been reported. 23, 24 Additionally, a recent study observed local recurrence in only 1 of 13 patients who received radiation for their RAAS versus 10 of 29 who underwent surgery alone. 25 Notwithstanding, the radiotherapy role in RAAS therapy remains uncertain.
Consistent with other reports, our analysis demonstrated significantly better survival for patients presenting with small and/or localized disease 7 ; moreover, our breast RAAS patients had a 5-year DSS better than that achieved in other postradiation sarcoma histologies; e.g., malignant peripheral nerve sheath tumor, osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma (5-year cumulative survival rates: 12, 31, 35, and 45 %, respectively). 18, 20, 26 The behavior of RAAS remains uncertain; some reports suggest prognosis inferior to sporadic counterparts, 25, 27, 28 whereas others report converse findings. 15, 16, 29 We observed a relatively indolent, good prognosis disease course, albeit with a 48 % local recurrence rate even in R0 patients, which is comparable to other RAAS series 14, 15, 29 but higher than for other STS contexts. 30, 31 Angiosarcoma is a multifocal disease characterized by microsatellite lesions that may comprise occult sarcoma spread beyond apparent R0 margins, as noted in other sarcoma subtypes [32] [33] [34] [35] ; hence, the significance of negative surgical margins is unclear, highlighting that surgery alone may not eradicate all disease.
In our series, 52 % of patients received chemotherapy in addition to surgery. In older series, lack of up-front chemotherapy or usage only for unresectable disease could underlie observed inferior outcomes. 28 However, other contemporary studies report favorable outcomes similar to ours; most patients in those series did not receive chemotherapy 15, 16, 29, 36 and so the role chemotherapy for RAAS remains uncertain. Yet to be established, unique features of breast angiosarcoma versus those originating in other anatomic regions also may be contributory, as noted in other reports. 7, 14, 15, 28 Although the risk of local recurrence was lower in patients who received chemotherapy, beneficial effects were not reflected in disease-specific or overall survival. However, our study is limited in its ability to establish possible chemotherapy benefits in RAAS. Only six pathology reports for patients who received neoadjuvant therapy indicated therapy-induced necrosis responses. Different chemotherapy regimens were utilized; limited numbers of patients in each subgroup suggest that these findings need to be explored in larger patient cohorts receiving standardized chemotherapy regimens, stratified for tumor burden. Phase II trials have demonstrated clinical benefit of paclitaxel treatment for unresectable angiosarcoma with a 74 % rate of nonprogression after two cycles. [37] [38] [39] Other groups have described promising responses to paclitaxel or gemcitabine-taxane (including complete remissions) for resectable primary or recurrent RAAS breast disease. [40] [41] [42] [43] These findings highlight the need for well-designed trials to inform the true utility of chemotherapy in this disease.
CONCLUSIONS
Although the incidence of RAAS is low, the number of cases reported is increasing as a function of the improved likelihood of surviving early-stage breast carcinoma. Furthermore, with increased use of external beam radiation for the management of breast cancer patients, the incidence of postradiation sarcomas may increase in the future. Long-term follow-up is needed for early disease detection. Complete surgical excision of angiosarcoma is the treatment of choice, without axillary dissection due to the low likelihood of axillary metastases. 7, 36, 44 Given the significant local recurrence rates, close monitoring is recommended. 14, 15, 36 Locally recurrent disease often is treatable; we have shown elsewhere that complete resection in this setting can potentially prolong survival. 45 Chemotherapy and radiotherapy may have roles to play in cases of unsuccessful surgical clearance; their beneficial effects remain to be defined. 24, 25, 37, 39, 41, 43, 46, 47 Accordingly, well-designed, multicenter, clinical trials are now urgently needed to advance RAAS care.
